Healthcare
Live Price
Offline$78.79
+7.61% today
1Y Change
-38.22%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TransMedics Group, Inc. (TMDX) is a Healthcare stock with a market cap of $3.45B and listed on NASDAQ. The stock last traded around $78.79 and down 38.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +37.1%, EPS growth of +423.4%, a dividend yield of 0.0%. What stands out right now is revenue +37.1%, EPS +423.4%, free cash flow +265.0% with operating margin 17.9% and ROIC 10.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.0 and price/sales 5.7. Stock Foundry combines TMDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMDX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TMDX Max Drawdown
-58.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TMDX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$30.3M
-67.6% YoY
FY Net Income
-$44.2M
-22.0% YoY
Free Cash Flow
-$32.4M
+43.9% YoY
Revenue Growth
+37.1%
EPS Growth
+423.4%
Gross Margin
59.9%
Net Margin
31.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 605M | 442M | 242M | 93M | 30M |
| Gross Profit | 363M | 262M | 154M | 65M | 21M |
| Operating Income | 109M | 37M | -29M | -31M | -39M |
| EBITDA | 148M | 70M | -8M | -29M | -38M |
| Net Income | 190M | 35M | -25M | -36M | -44M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 488M | 337M | 395M | 201M | 26M |
| Total Assets | 1.1B | 804M | 706M | 277M | 135M |
| Total Liabilities | 595M | 575M | 569M | 90M | 67M |
| Shareholder Equity | 473M | 229M | 137M | 187M | 68M |
| Total Debt | 470M | 518M | 516M | 68M | 44M |
| Net Debt | -19M | 182M | 121M | -134M | 18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
+37.0% YoY
Capital Expenditures
4M
+70.4% YoY
Free Cash Flow
32M
+43.9% YoY
Key ratios
Gross Margin
59.9%
Operating Margin
17.9%
Net Margin
31.4%
ROE
53.9%
Debt / Equity
0.99x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.